KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBT Margin (2016 - 2025)

Boston Scientific (BSX) has disclosed EBT Margin for 17 consecutive years, with 13.24% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 42.0% to 13.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16.86% through Dec 2025, up 323.0% year-over-year, with the annual reading at 16.86% for FY2025, 324.0% up from the prior year.
  • EBT Margin hit 13.24% in Q4 2025 for Boston Scientific, down from 18.54% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18.59% in Q2 2025 to a low of 3.81% in Q4 2021.
  • Historically, EBT Margin has averaged 12.54% across 5 years, with a median of 12.96% in 2023.
  • Biggest five-year swings in EBT Margin: soared 2501bps in 2021 and later plummeted -874bps in 2022.
  • Year by year, EBT Margin stood at 3.81% in 2021, then skyrocketed by 221bps to 12.21% in 2022, then grew by 11bps to 13.56% in 2023, then decreased by -5bps to 12.83% in 2024, then grew by 3bps to 13.24% in 2025.
  • Business Quant data shows EBT Margin for BSX at 13.24% in Q4 2025, 18.54% in Q3 2025, and 18.59% in Q2 2025.